Jan 22, 2018 - Waltham-based Bioverativ, a hemophilia drugmaker that was spun out of Biogen last year, has around 275 employees in the state.
Jan 22, 2018 - Biotech continues to underperform the overall market as money flow heads to the more direct beneficiaries of tax reform within sectors and industries. However, that could very well change if M&A activ
Jan 22, 2018 - Sanofi (SNY) is set to acquire blood disorder focused biopharmaceutical company, Bioverativ, for $11.6 billion.
Jan 22, 2018 - Here is a look at four large-cap pharma and biotech stocks including Merck (MRK) that could surpass earnings expectations in the fourth quarter.
Jan 22, 2018 - The $11.6 billion deal for Bioverativ would bolster the French pharmaceutical giant’s portfolio as it faces falling sales for its diabetes drug, Lantus.
Jan 22, 2018 - Paris-based Sanofi SA, the state’s largest biotech employer, said Monday that it will buy hemophilia drugmaker Bioverativ for $11.6 billion, one year after the Waltham company was spun out of Biogen.
Sanofi (NYSE: SNY), the parent company of Cambridge-based Sanofi Genzyme, said it will pay $105 per share in cash for Bioverativ (Nasdaq: BIVV), which spun out of Biogen (Nasdaq: BIIB) last January. The price represents a 63 percent premium to Bioverativ’s share price as of Friday.
The deal is…
Jan 22, 2018 - As the government shutdown enters a third day, U.S. futures are edging down, the dollar is pulling back slightly and Treasury yields are touching 3 1/2-year highs. We have to see if this event is a t
Jan 22, 2018 - Sanofi (NYSE:SNY) is close to acquiring Bioverativ (NASDAQ:BIVV) for $105 a share, valuing the hemophilia drug maker - separated from Biogen (NASDAQ:BIIB) last year - at about $11.6B, according to mul
Jan 17, 2018 - Novo Nordisk has made a $3.1B bid on the Belgian biotech Ablynx.The Danish insulin giant needs acquisitions to turn to growth again.There are probably more pharma giants interested in Ablynx.Ablynx's
Jan 17, 2018 - Addressing a significant concern in the medical community by providing a pain management system without addictive properties.Two upcoming catalysts are possible drivers of share price.Early data has b